Analysts Set AtriCure, Inc. (NASDAQ:ATRC) Price Target at $48.50

Shares of AtriCure, Inc. (NASDAQ:ATRC) have been assigned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $48.50.

A number of analysts have recently issued reports on the company. Raymond James Financial set a $52.00 price objective on AtriCure in a research report on Tuesday, July 21st. Weiss Ratings upgraded AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research report on Tuesday, July 28th. Wall Street Zen downgraded shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Canaccord Genuity Group raised their price target on shares of AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Finally, UBS Group cut their price objective on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th.

AtriCure Price Performance

ATRC stock opened at $41.39 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The stock has a market capitalization of $2.11 billion, a P/E ratio of 197.10 and a beta of 1.20. AtriCure has a fifty-two week low of $25.36 and a fifty-two week high of $43.18. The business has a 50-day moving average of $32.25 and a 200-day moving average of $31.33.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The firm had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter in the prior year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, sell-side analysts anticipate that AtriCure will post 0.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Justin J. Noznesky sold 6,182 shares of the business’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total transaction of $239,861.60. Following the transaction, the insider owned 100,219 shares in the company, valued at $3,888,497.20. The trade was a 5.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Karen Prange sold 3,564 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total transaction of $138,283.20. Following the transaction, the director directly owned 22,809 shares in the company, valued at approximately $884,989.20. This represents a 13.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 47,246 shares of company stock worth $1,777,845 over the last ninety days. 4.00% of the stock is owned by company insiders.

Institutional Trading of AtriCure

Several large investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in AtriCure during the 2nd quarter worth approximately $125,198,000. Marshall Wace LLP increased its holdings in shares of AtriCure by 63.4% during the fourth quarter. Marshall Wace LLP now owns 913,453 shares of the medical device company’s stock valued at $36,136,000 after acquiring an additional 354,281 shares in the last quarter. Wellington Management Group LLP raised its position in shares of AtriCure by 8.1% during the third quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock worth $151,296,000 after purchasing an additional 322,818 shares during the period. First Light Asset Management LLC raised its position in shares of AtriCure by 32.0% during the fourth quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company’s stock worth $46,501,000 after purchasing an additional 285,083 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of AtriCure in the 1st quarter worth $7,922,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.